Catalysts / CNTX
Upcoming FDA decisions and readouts we track for Context Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Context Therapeutics (CNTX, listed on Nasdaq). They cover 2 programmes: CTIM-76 (Platinum-resistant ovarian cancer (Claudin 6 x CD3)) and CT-202 (Urothelial, colorectal and triple-negative breast cancer (Nectin-4 x CD3)).
First on the list: the Phase 1 readout for CTIM-76 (Platinum-resistant ovarian cancer (Claudin 6 x CD3)), guided by the company to Q2 2027. By stage, the upcoming rows are 2 Phase 1 readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Context Therapeutics CNTX · Nasdaq | CTIM-76 | Platinum-resistant ovarian cancer (Claudin 6 x CD3) | Q2 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Context Therapeutics CNTX · Nasdaq | CT-202 | Urothelial, colorectal and triple-negative breast cancer (Nectin-4 x CD3) | H2 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList